Personal information

Other IDs

Scopus Author ID: 20336652400

Activities

Collapse all

Works (50 of 114)

Items per page:
Page 1 of 3

Treatment of Pleural Mesothelioma: ASCO Guideline Update

Journal of Clinical Oncology
2025-03-10 | Journal article
DOI: 10.1200/JCO-24-02425
Contributors: Hedy L. Kindler; Nofisat Ismaila; Lyudmila Bazhenova; Quincy Chu; Jane E. Churpek; Ibiayi Dagogo-Jack; Darren S. Bryan; Michael W. Drazer; Patrick Forde; Aliya N. Husain et al.
Source: check_circle
Crossref

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2

Journal of Clinical Oncology
2024-12-20 | Journal article
DOI: 10.1200/JCO-24-02133
Contributors: Lyudmila Bazhenova; Nofisat Ismaila; Fawzi Abu Rous; Krishna Alluri; Janet Freeman-Daily; Balazs Halmos; Narinder Malhotra; Kristen A. Marrone; Sonam Puri; Angel Qin et al.
Source: check_circle
Crossref

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

Future Oncology
2024-12-13 | Journal article
DOI: 10.1080/14796694.2024.2418285
Contributors: Lyudmila Bazhenova; Dong-Wan Kim; Byoung Chul Cho; Sanjay Goel; Rebecca Heist; Theresa L Werner; Keith D Eaton; Judy S Wang; Shubham Pant; Douglas R Adkins et al.
Source: check_circle
Crossref

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Cancers
2024-03-22 | Journal article
DOI: 10.3390/cancers16071252
Contributors: Karen M. Yun; Lyudmila Bazhenova
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome

JCO Precision Oncology
2024-02 | Journal article
DOI: 10.1200/PO.23.00265
Contributors: Karen M. Yun; Anna Narezkina; Charles Redfern; Katherine Velasco; Lyudmila Bazhenova
Source: check_circle
Crossref

Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-07-26 | Preprint
DOI: 10.1158/2159-8290.c.6549404
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-07-26 | Preprint
DOI: 10.1158/2159-8290.23772472
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-07-26 | Preprint
DOI: 10.1158/2159-8290.23772472.v1
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

JCO Clinical Cancer Informatics
2023-04 | Journal article
DOI: 10.1200/CCI.22.00165
Contributors: Shing M. Lee; Weijia Fan; Aijin Wang; Riha Vaidya; Mary W. Redman; Scott N. Gettinger; Lyudmila Bazhenova; Roy S. Herbst; Dawn L. Hershman; Joseph M. Unger
Source: check_circle
Crossref

Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-04-03 | Preprint
DOI: 10.1158/2159-8290.c.6549404.v1
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-04-03 | Preprint
DOI: 10.1158/2159-8290.22540541
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial

2023-04-03 | Preprint
DOI: 10.1158/2159-8290.22540541.v1
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref

Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530504
Contributors: Edward B. Garon; Alexander I. Spira; Melissa Johnson; Lyudmila Bazhenova; Joseph Leach; Amy L. Cummings; Albert Candia; Robert L. Coffman; Mary J. Janatpour; Robert Janssen et al.
Source: check_circle
Crossref

Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6530504.v1
Contributors: Edward B. Garon; Alexander I. Spira; Melissa Johnson; Lyudmila Bazhenova; Joseph Leach; Amy L. Cummings; Albert Candia; Robert L. Coffman; Mary J. Janatpour; Robert Janssen et al.
Source: check_circle
Crossref

Supplementary Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480679
Contributors: Edward B. Garon; Alexander I. Spira; Melissa Johnson; Lyudmila Bazhenova; Joseph Leach; Amy L. Cummings; Albert Candia; Robert L. Coffman; Mary J. Janatpour; Robert Janssen et al.
Source: check_circle
Crossref

Supplementary Data from A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22480679.v1
Contributors: Edward B. Garon; Alexander I. Spira; Melissa Johnson; Lyudmila Bazhenova; Joseph Leach; Amy L. Cummings; Albert Candia; Robert L. Coffman; Mary J. Janatpour; Robert Janssen et al.
Source: check_circle
Crossref

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer

Cancer Medicine
2022 | Journal article
DOI: 10.1002/cam4.4635
EID:

2-s2.0-85126533919

Part of ISSN: 20457634
Contributors: Solomon, B.; Callejo, A.; Bar, J.; Berchem, G.; Bazhenova, L.; Saintigny, P.; Wunder, F.; Raynaud, J.; Girard, N.; Lee, J.J. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy

Lung Cancer
2022 | Journal article
DOI: 10.1016/j.lungcan.2022.03.005
EID:

2-s2.0-85130865319

Part of ISSN: 18728332 01695002
Contributors: Minchom, A.; Viteri, S.; Bazhenova, L.; Gadgeel, S.M.; Ou, S.-H.I.; Trigo, J.; Bauml, J.M.; Backenroth, D.; Bhattacharya, A.; Li, T. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy

Translational Lung Cancer Research
2022 | Journal article
DOI: 10.21037/tlcr-21-665
EID:

2-s2.0-85128515665

Part of ISSN: 22264477 22186751
Contributors: Yu, L.; Bazhenova, L.; Gold, K.; Tran, L.; Hilburn, V.; Vu, P.; Patel, S.P.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Erratum: Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors (Clinical cancer research : an official journal of the American Association for Cancer Research (2022) 28 7 (1302-1312))

Clinical cancer research : an official journal of the American Association for Cancer Research
2022 | Journal article
DOI: 10.1158/1078-0432.CCR-22-1108
EID:

2-s2.0-85130033704

Part of ISSN: 15573265
Contributors: Demetri, G.D.; De Braud, F.; Drilon, A.; Siena, S.; Patel, M.R.; Cho, B.C.; Liu, S.V.; Ahn, M.-J.; Chiu, C.-H.; Lin, J.J. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Cancer Management and Research
2022 | Journal article
DOI: 10.2147/CMAR.S283199
EID:

2-s2.0-85125598536

Part of ISSN: 11791322
Contributors: Yun, K.M.; Bazhenova, L.A.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Clinical Cancer Research
2022 | Journal article
DOI: 10.1158/1078-0432.CCR-21-3597
EID:

2-s2.0-85128000950

Part of ISSN: 15573265 10780432
Contributors: Demetri, G.D.; De Braud, F.; Drilon, A.; Siena, S.; Patel, M.R.; Cho, B.C.; Liu, S.V.; Ahn, M.-J.; Chiu, C.-H.; Lin, J.J. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment

JCO Precision Oncology
2022-12 | Journal article
DOI: 10.1200/PO.21.00551
Contributors: Nicholas P. Giustini; Sandip Pravin Patel; Nathaniel J. Myall; José Fernando do Prado Moura; Amit Kulkarni; Richard C. Chao; Heather Wakelee; Lyudmila Bazhenova
Source: check_circle
Crossref

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Journal of Clinical Oncology
2022-08-10 | Journal article
DOI: 10.1200/JCO.21.02752
Contributors: Sai-Hong Ignatius Ou; Pasi A. Jänne; Ticiana A. Leal; Igor I. Rybkin; Joshua K. Sabari; Minal A. Barve; Lyudmila Bazhenova; Melissa L. Johnson; Karen L. Velastegui; Cornelius Cilliers et al.
Source: check_circle
Crossref

Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

New England Journal of Medicine
2022-01-20 | Journal article
DOI: 10.1056/NEJMoa2112431
Contributors: Bob T. Li; Egbert F. Smit; Yasushi Goto; Kazuhiko Nakagawa; Hibiki Udagawa; Julien Mazières; Misako Nagasaka; Lyudmila Bazhenova; Andreas N. Saltos; Enriqueta Felip et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance?

Journal of Thoracic and Cardiovascular Surgery
2021 | Journal article
DOI: 10.1016/j.jtcvs.2020.06.109
EID:

2-s2.0-85100687026

Part of ISSN: 1097685X 00225223
Contributors: Bazhenova, L.; Urbanic, J.; Onaitis, M.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations

Lung Cancer
2021 | Journal article
DOI: 10.1016/j.lungcan.2021.10.020
EID:

2-s2.0-85119410299

Part of ISSN: 18728332 01695002
Contributors: Bazhenova, L.; Minchom, A.; Viteri, S.; Bauml, J.M.; Ignatius Ou, S.-H.; Gadgeel, S.M.; Trigo, J.M.; Backenroth, D.; Li, T.; Londhe, A. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

JTO Clinical and Research Reports
2021 | Journal article
DOI: 10.1016/j.jtocrr.2020.100114
EID:

2-s2.0-85102035727

Part of ISSN: 26663643
Contributors: Yang, J.C.-H.; Reckamp, K.L.; Kim, Y.-C.; Novello, S.; Smit, E.F.; Lee, J.-S.; Su, W.-C.; Akerley, W.L.; Blakely, C.M.; Groen, H.J.M. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Intracranial efficacy of selpercatinib in RET fusion-positive non–small cell lung cancers on the LIBRETTO-001 trial

Clinical Cancer Research
2021 | Journal article
DOI: 10.1158/1078-0432.CCR-21-0800
EID:

2-s2.0-85111700467

Part of ISSN: 15573265 10780432
Contributors: Subbiah, V.; Gainor, J.F.; Oxnard, G.R.; Tan, D.S.W.; Owen, D.H.; Cho, B.C.; Loong, H.H.; McCoach, C.E.; Weiss, J.; Kim, Y.J. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Nivolumab plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

JAMA Oncology
2021 | Journal article
DOI: 10.1001/jamaoncol.2021.2209
EID:

2-s2.0-85110736233

Part of ISSN: 23742445 23742437
Contributors: Gettinger, S.N.; Redman, M.W.; Bazhenova, L.; Hirsch, F.R.; Mack, P.C.; Schwartz, L.H.; Bradley, J.D.; Stinchcombe, T.E.; Leighl, N.B.; Ramalingam, S.S. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (Nsclc) with immune checkpoint inhibitors (icis)

Lung Cancer: Targets and Therapy
2021 | Journal article
DOI: 10.2147/LCTT.S235102
EID:

2-s2.0-85106284800

Part of ISSN: 11792728
Contributors: Giustini, N.; Bazhenova, L.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting

Targeted Oncology
2021 | Journal article
DOI: 10.1007/s11523-021-00815-4
EID:

2-s2.0-85105137766

Part of ISSN: 1776260X 17762596
Contributors: Bazhenova, L.; Lokker, A.; Snider, J.; Castellanos, E.; Fisher, V.; Fellous, M.; Nanda, S.; Zong, J.; Keating, K.; Jiao, X.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer

Lung Cancer
2021 | Journal article
DOI: 10.1016/j.lungcan.2021.06.028
EID:

2-s2.0-85111061431

Part of ISSN: 18728332 01695002
Contributors: Kozono, D.E.; Stinchcombe, T.E.; Salama, J.K.; Bogart, J.; Petty, W.J.; Guarino, M.J.; Bazhenova, L.; Larner, J.M.; Weiss, J.; DiPetrillo, T.A. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer

Expert Opinion on Pharmacotherapy
2021-09-22 | Journal article
DOI: 10.1080/14656566.2021.1948014
Contributors: Shiruyeh Schokrpur; Van Hilburn; Nicholas Giustini; Lyudmila Bazhenova
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Clinical Cancer Research
2021-08-15 | Journal article
DOI: 10.1158/1078-0432.CCR-21-0263
Contributors: Edward B. Garon; Alexander I. Spira; Melissa Johnson; Lyudmila Bazhenova; Joseph Leach; Amy L. Cummings; Albert Candia; Robert L. Coffman; Mary J. Janatpour; Robert Janssen et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Cancer Discovery
2021-07-01 | Journal article
DOI: 10.1158/2159-8290.CD-20-1598
Contributors: Gregory J. Riely; Joel W. Neal; D. Ross Camidge; Alexander I. Spira; Zofia Piotrowska; Daniel B. Costa; Anne S. Tsao; Jyoti D. Patel; Shirish M. Gadgeel; Lyudmila Bazhenova et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Targeted Therapy

Clinics in Chest Medicine
2020 | Journal article
DOI: 10.1016/j.ccm.2020.02.003
EID:

2-s2.0-85084626934

Part of ISSN: 15578216 02725231
Contributors: Giustini, N.P.; Jeong, A.-R.; Buturla, J.; Bazhenova, L.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Co-occurring alterations in the RAS–MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer

Clinical Cancer Research
2020 | Journal article
DOI: 10.1158/1078-0432.CCR-19-1667
EID:

2-s2.0-85077927579

Part of ISSN: 15573265 10780432
Contributors: Rotow, J.K.; Gui, P.; Wu, W.; Raymond, V.M.; Lanman, R.B.; Kaye, F.J.; Peled, N.; Fece de la Cruz, F.; Nadres, B.; Corcoran, R.B. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

New England Journal of Medicine
2020 | Journal article
DOI: 10.1056/NEJMoa2005653
EID:

2-s2.0-85089958597

Part of ISSN: 15334406 00284793
Contributors: Drilon, A.; Oxnard, G.R.; Tan, D.S.W.; Loong, H.H.F.; Johnson, M.; Gainor, J.; McCoach, C.E.; Gautschi, O.; Besse, B.; Cho, B.C. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

The Lancet Oncology
2020 | Journal article
DOI: 10.1016/S1470-2045(19)30691-6
EID:

2-s2.0-85078321993

Part of ISSN: 14745488 14702045
Contributors: Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

ROS1-rearranged Non-small Cell Lung Cancer

Thoracic surgery clinics
2020 | Journal article
DOI: 10.1016/j.thorsurg.2020.01.007
EID:

2-s2.0-85084031057

Part of ISSN: 15585069
Contributors: Giustini, N.P.; Bazhenova, L.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Journal of Thoracic Oncology
2020 | Journal article
DOI: 10.1016/j.jtho.2020.09.001
EID:

2-s2.0-85092734124

Part of ISSN: 15561380 15560864
Contributors: Yang, J.C.-H.; Camidge, D.R.; Yang, C.-T.; Zhou, J.; Guo, R.; Chiu, C.-H.; Chang, G.-C.; Shiah, H.-S.; Chen, Y.; Wang, C.-C. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

A phase I/IB trial of the vegfr-sparing multikinase ret inhibitor RXDX-105

Cancer Discovery
2019 | Journal article
DOI: 10.1158/2159-8290.CD-18-0839
EID:

2-s2.0-85063573548

Part of ISSN: 21598290 21598274
Contributors: Drilon, A.; Fu, S.; Patel, M.R.; Fakih, M.; Wang, D.; Olszanski, A.J.; Morgensztern, D.; Liu, S.V.; Cho, B.C.; Bazhenova, L. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Anaplastic Lymphoma Kinase

Current Cancer Research
2019 | Book chapter
DOI: 10.1007/978-3-030-17832-1_2
EID:

2-s2.0-85111808054

Part of ISSN: 21992592 21992584
Contributors: Villanueva, N.A.; Giustini, N.P.; Bazhenova, L.A.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer

Journal of Translational Medicine
2019 | Journal article
DOI: 10.1186/s12967-019-2035-8
EID:

2-s2.0-85071642112

Part of ISSN: 14795876
Contributors: Shishido, S.N.; Carlsson, A.; Nieva, J.; Bethel, K.; Hicks, J.B.; Bazhenova, L.; Kuhn, P.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

JAMA Oncology
2019 | Journal article
DOI: 10.1001/jamaoncol.2019.1847
EID:

2-s2.0-85070549292

Part of ISSN: 23742445 23742437
Contributors: Stinchcombe, T.E.; Jänne, P.A.; Wang, X.; Bertino, E.M.; Weiss, J.; Bazhenova, L.; Gu, L.; Lau, C.; Paweletz, C.; Jaslowski, A. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer

SSRN
2019 | Other
DOI: 10.2139/ssrn.3495608
EID:

2-s2.0-85109295792

Part of ISSN: 15565068
Contributors: Yang, J.C.-H.; Camidge, D.R.; Yang, C.-T.; Zhou, J.; Guo, R.; Chiu, C.-H.; Chang, G.-C.; Shiah, H.-S.; Chen, Y.; Wang, C.-C. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib

Journal of Thoracic Oncology
2019 | Journal article
DOI: 10.1016/j.jtho.2019.04.028
EID:

2-s2.0-85067672615

Part of ISSN: 15561380 15560864
Contributors: Camidge, D.R.; Pabani, A.; Miller, R.M.; Rizvi, N.A.; Bazhenova, L.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation

Clinical Cancer Research
2019 | Journal article
DOI: 10.1158/1078-0432.CCR-18-3829
EID:

2-s2.0-85066614868

Part of ISSN: 15573265 10780432
Contributors: Brown, B.P.; Zhang, Y.-K.; Westover, D.; Yan, Y.; Qiao, H.; Huang, V.; Du, Z.; Smith, J.A.; Ross, J.S.; Miller, V.A. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier

Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies

Cancer
2019 | Journal article
DOI: 10.1002/cncr.31891
EID:

2-s2.0-85057748059

Part of ISSN: 10970142 0008543X
Contributors: Ahn, M.-J.; Tsai, C.-M.; Shepherd, F.A.; Bazhenova, L.; Sequist, L.V.; Hida, T.; Yang, J.C.H.; Ramalingam, S.S.; Mitsudomi, T.; Jänne, P.A. et al.
Source: Self-asserted source
Lyudmila Bazhenova via Scopus - Elsevier
Items per page:
Page 1 of 3

Peer review (6 reviews for 3 publications/grants)

Review activity for Journal of cancer research and clinical oncology. (1)
Review activity for JTO clinical and research reports. (4)
Review activity for Targeted oncology. (1)
How many people are using ORCID?